D.A. Davidson & CO. Boosts Holdings in Novo Nordisk A/S (NYSE:NVO)

D.A. Davidson & CO. raised its position in shares of Novo Nordisk A/S (NYSE:NVO) by 13.4% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 26,565 shares of the company’s stock after buying an additional 3,129 shares during the quarter. D.A. Davidson & CO.’s holdings in Novo Nordisk A/S were worth $2,748,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also made changes to their positions in the business. Sachetta LLC purchased a new position in shares of Novo Nordisk A/S during the fourth quarter valued at approximately $34,000. Clearbridge Investments LLC raised its holdings in shares of Novo Nordisk A/S by 4.0% during the 4th quarter. Clearbridge Investments LLC now owns 2,314,261 shares of the company’s stock worth $239,410,000 after acquiring an additional 89,152 shares in the last quarter. Balentine LLC lifted its holdings in shares of Novo Nordisk A/S by 18.6% in the 4th quarter. Balentine LLC now owns 81,304 shares of the company’s stock valued at $8,411,000 after acquiring an additional 12,741 shares during the last quarter. Thoroughbred Financial Services LLC increased its position in Novo Nordisk A/S by 77.6% during the fourth quarter. Thoroughbred Financial Services LLC now owns 34,704 shares of the company’s stock valued at $3,590,000 after acquiring an additional 15,167 shares during the last quarter. Finally, Mckinley Capital Management LLC grew its stake in shares of Novo Nordisk A/S by 78.5% during the fourth quarter. Mckinley Capital Management LLC now owns 10,584 shares of the company’s stock valued at $1,095,000 after buying an additional 4,654 shares during the last quarter. Institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Stock Performance

NVO stock traded up $0.47 during trading on Friday, hitting $136.04. 2,845,222 shares of the company’s stock traded hands, compared to its average volume of 4,075,833. The stock has a fifty day moving average price of $128.21 and a two-hundred day moving average price of $116.45. The company has a quick ratio of 0.50, a current ratio of 0.70 and a debt-to-equity ratio of 0.17. Novo Nordisk A/S has a 52 week low of $75.56 and a 52 week high of $138.28. The stock has a market capitalization of $610.48 billion, a price-to-earnings ratio of 46.90, a price-to-earnings-growth ratio of 1.40 and a beta of 0.43.

Novo Nordisk A/S (NYSE:NVO) last announced its earnings results on Thursday, May 2nd. The company reported $0.83 earnings per share for the quarter, beating the consensus estimate of $0.77 by $0.06. Novo Nordisk A/S had a return on equity of 91.70% and a net margin of 36.56%. The firm had revenue of $9.52 billion for the quarter, compared to the consensus estimate of $9.23 billion. As a group, equities analysts anticipate that Novo Nordisk A/S will post 3.43 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

NVO has been the topic of several research reports. BMO Capital Markets assumed coverage on Novo Nordisk A/S in a research report on Friday, April 12th. They issued an “outperform” rating and a $163.00 target price on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $160.00 price objective on shares of Novo Nordisk A/S in a report on Thursday, April 18th. Two analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $133.60.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.